Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Co-Treatment Of Hairy Cell Leukemia and Melanoma With The BRAF Inhibitor Dabrafenib

Leslie A. Andritsos, MD, James S. Blachly, MD, Kari Kendra, M.D., Gerard Lozanski, M.D., Michael R. Grever, MD

Blood (2013) 122 (21): 5311.

https://doi.org/10.1182/blood.V122.21.5311.5311

Published: 2013

Journal Articles

Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma

Craig C. Hofmeister, MD, Mindy A Bowers, BS, Anissa Bingman, M.S., Gerard Lozanski, M.D., Robert A. Baiocchi, M.D., Ph.D., William Falk, B.S., Don M. Benson, Jr., MD, PhD, Yvonne A Efebera, M.D., Kristina Humphries, M.S., Megan Sell, RN, MS, Carli N Greenfield, RN, MSN, ACNP, Mark E Lustberg, MD, PhD, John L. Vaughn, BS, Christian Tyler Earl, Susan Geyer, PhD, Steven M. Devine, MD

Blood (2012) 120 (21): 4460.

https://doi.org/10.1182/blood.V120.21.4460.4460

Published: 2012

Journal Articles

Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance

Craig C. Hofmeister, MD, Mindy A Bowers, BS, Robert A. Baiocchi, M.D., Ph.D., Gerard Lozanski, M.D., Kristina Humphries, M.S., Kristie A. Blum, MD, Pierluigi Porcu, MD, Sam Penza, MD, Carli N Greenfield, RN, MSN, ACNP, Megan Sell, RN, MS, Christian Tyler Earl, Joseph Zitesman, B.S., Carl Quinion, Mark E Lustberg, MD, PhD, Leslie A Andritsos, MD, Steven M. Devine, MD

Blood (2012) 120 (21): 2004.

https://doi.org/10.1182/blood.V120.21.2004.2004

Published: 2012

Journal Articles

Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)

Sumithira Vasu, MBBS, Samantha M. Jaglowski, MD, MPH, Susan Geyer, PhD, Anissa Bingman, M.S., Patrick Elder, M.S., Jianhua Yu, PhD, Leslie A Andritsos, MD, William Blum, MD, Rebecca B Klisovic, MD, Sam Penza, MD, Yvonne A Efebera, M.D., Craig C. Hofmeister, MD, Don M. Benson, Jr., MD, PhD, Natarajan Muthusamy, DVM, Ph.D, Steven M. Devine, MD, Gerard Lozanski, M.D.

Blood (2012) 120 (21): 4192.

https://doi.org/10.1182/blood.V120.21.4192.4192

Published: 2012

Journal Articles

Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).

Jonathon B. Cohen, MD, Susan Geyer, PhD, Gerard Lozanski, M.D., Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Jeffrey A. Jones, MD, MPH, Pierluigi Porcu, MD, Beth Christian, MD, Robert A. Baiocchi, M.D., Ph.D., Kami Maddocks, MD, Joseph M. Flynn, DO, MPH, Steven M. Devine, MD, Kristie A. Blum, MD

Blood (2012) 120 (21): 2693.

https://doi.org/10.1182/blood.V120.21.2693.2693

Published: 2012

Journal Articles

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).

Wendy Stock, MD, Ben Sanford, M.A., Gerard Lozanski, M.D., Ravi Vij, MD, John C. Byrd, Bayard L. Powell, MD, Meir Wetzler, MD, Dorie Sher, B.S., Colin Edwards, Ph.D., Michael Kelly, B.S., Sue Richards, Ph.D, Crystal Sung, PhD, Greg Malnassy, B.S., Eva Hoke, BA, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2009) 114 (22): 838.

https://doi.org/10.1182/blood.V114.22.838.838

Published: 2009

Journal Articles

del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement.

Leslie A. Andritsos, MD, Jeffrey Jones, M.D., Gerard Lozanski, M.D., Thomas S. Lin, M.D., Kristie A. Blum, M.D., Michael R. Grever, M.D., David Jarjoura, Ph.D., John C. Byrd, M.D., Nyla Heerema, M.D.

Blood (2007) 110 (11): 2073.

https://doi.org/10.1182/blood.V110.11.2073.2073

Published: 2007

Journal Articles

Humanized Anti CD-40 Antibody SGN-40 Effectively Induces Cytotoxicity Against Chronic Lymphocytic Leukemia (CLL) Cells through Antibody Mediated Cytotoxicity and Demonstrates Modest Biologic Evidence of CD40 Activation.

Aruna C. Gowda, MD, Xiaobin B. Zhao, M.S, Carolyn Cheney, BS, Najma Mehter, BS, Gerard Lozanski, M.D, Thomas S. Lin, M.D PhD, Sara Guster, M.S, J. G. Drachman, M.D, Natarajan Muthusamy, DvM, PhD, John C. Byrd, M.D

Blood (2005) 106 (11): 2966.

https://doi.org/10.1182/blood.V106.11.2966.2966

Published: 2005

NARROW

Co-Treatment Of Hairy Cell Leukemia and Melanoma With The BRAF Inhibitor Dabrafenib

Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma

Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance

Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)

Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).

del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement.

Humanized Anti CD-40 Antibody SGN-40 Effectively Induces Cytotoxicity Against Chronic Lymphocytic Leukemia (CLL) Cells through Antibody Mediated Cytotoxicity and Demonstrates Modest Biologic Evidence of CD40 Activation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only